Neuroantibody Biomarkers : Links and Challenges in Environmental Neurodegeneration and Autoimmunity

Abstract EN

The majority of neurodegenerative (ND) and autoimmune diseases (AID) remain idiopathic.

The contribution of environmental chemicals to the development of these disorders has become of great interest in recent years.

A convergence of mechanism between of ND and AID development has also emerged.

In the case of ND, including neurotoxicity, the focus of this review, work over the last two decade in the realm of biomarker development, indicates that the immune response provides a venue whereby humoral immunity, in the form of autoantibodies to nervous system specific proteins, or neuroantibodies (NAb), may provide, once validated, a sensitive high throughput surrogate biomarker of effect with the potential of predicting outcome in absence of overt neurotoxicity/neurodegeneration.

In addition, NAb may prove to be a contributor to the progression of the nervous system pathology, as well as biomarker of stage and therapeutic efficacy.

There is a compelling need for biomarkers of effect in light of the introduction of new chemicals, such as nanoengineered material, where potential neurotoxicity remains to be defined.

Furthermore, the convergence of mechanisms associated with ND and AID draws attention to the neglected arena of angiogenesis in defining the link between environment, ND, and AID.